Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Alpha-Synuclein Gene (SNCA) is a Genomic Target of Methyl-CpG Binding Protein 2 (MeCP2)-Implications for Parkinson's Disease and Rett Syndrome.

Molecular neurobiology - 1 Oct 2024

Schmitt Ina, Evert Bernd O, Sharma Amit, Khazneh Hassan, Murgatroyd Chris, Wüllner Ullrich

Abstract excerpt

Mounting evidence suggests a prominent role for alpha-synuclein (a-syn) in neuronal cell function. Alterations in the levels of cellular a-syn have been hypothesized to play a critical role in the development of Parkinson's disease (PD); however, mechanisms that control expression of the gene for a-syn (SNCA) in cis and trans as well as turnover of a-syn are not well understood. We analyzed whether methyl-CpG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Introns

Share to Methyl-CpG-Binding Protein 2

Share to Parkinson Disease

Share to Protein Binding

Share to Rett Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 38429622
DOI: 10.1007/s12035-024-03974-3
PMCID: PMC11415397

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Alpha-Synuclein Gene (SNCA) is a Genomic Target of Methyl-CpG Binding Protein 2 (MeCP2)-Implications for Parkinson's Disease and Rett Syndrome.PMID 38429622Read ↗

Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.Semantic proximity Read ↗

CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.Semantic proximity Read ↗

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathiesSemantic proximity Read ↗

[Neurodegeneration and epigenetics].Semantic proximity Read ↗

<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse modelSemantic proximity Read ↗

SNCA Gene Methylation in Parkinson’s Disease and Multiple System AtrophySemantic proximity Read ↗

Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression.Semantic proximity Read ↗

Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's diseaseSemantic proximity Read ↗

The yin and yang of α-synuclein-associated epigenetics in Parkinson’s diseaseSemantic proximity Read ↗

Discovery of functional non-coding conserved regions in the α-synuclein gene locusSemantic proximity Read ↗

Parkinson's disease correlates with promoter methylation in the α-synuclein gene.Semantic proximity Read ↗

Alpha-synuclein induces epigenomic dysregulation of glutamate signaling and locomotor pathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.